middle.news
Anatara Lifesciences’ GaRP-IBS Trial Misses Primary Endpoint but Reveals Key Secondary Benefits
4:06am on Monday 2nd of June, 2025 AEST
•
Healthcare
Read Story
Anatara Lifesciences’ GaRP-IBS Trial Misses Primary Endpoint but Reveals Key Secondary Benefits
4:06am on Monday 2nd of June, 2025 AEST
Key Points
GaRP-IBS Phase II trial Stage 2 completed with primary endpoint unmet
Secondary endpoints show statistically significant anxiety reduction and adequate relief
Anti-obesity pre-clinical studies commenced with University of Newcastle
Cash reserves declined to $0.393 million with net outflows of $0.66 million in Q3 FY25
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Anatara Lifesciences (ASX:ANR)
OPEN ARTICLE